info@marketresearchfuture.com   ๐Ÿ“ž  +1 (855) 661-4441(US)   ๐Ÿ“ž  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major playersโ€™ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Acute Pancreatitis Market Research Report Information By Cause (Gallstones, Alcohol and Others), By Treatment (Intravenous Fluid, Nutritional Support, Analgesics, Endoscopic Retrograde Cholangiopancreatography (ERCP) and Others), By Diagnosis (Imaging Tests and Laboratory Tests), By End-User (Hospitals, Clinics and Others), and By Region (North America, Europe, Asia-Pacific, And Rest Of The World) โ€“ Market Forecast Till 2032


ID: MRFR/Pharma/1036-CR | 118 Pages | Author: Rahul Gotadki| December 2019

ย 


Market Segmentation Tab


Acute Pancreatitis Cause Outlook (USD Billion, 2018-2030)



  • Gallstones

  • Alcohol

  • Others


Acute Pancreatitis Treatment Outlook (USD Billion, 2018-2030)



  • Intravenous fluid

  • Nutritional support

  • Analgesics

  • Endoscopic Retrograde Cholangiopancreatography (ERCP)

  • Others


Acute Pancreatitis Diagnosis Outlook (USD Billion, 2018-2030)



  • Imaging Tests

  • Laboratory Tests


Acute Pancreatitis End-user Outlook (USD Billion, 2018-2030)



  • Hospitals

  • Clinics

  • Others


Acute Pancreatitis Regional Outlook (USD Billion, 2018-2030)




  • North America Outlook (USD Billion, 2018-2030)


    • North America Acute Pancreatitis by Cause

      • Gallstones

      • Alcohol

      • Others




    • North America Acute Pancreatitis by Treatment

      • Intravenous fluid

      • Nutritional support

      • Analgesics

      • Endoscopic Retrograde Cholangiopancreatography (ERCP)

      • Others




    • North America Acute Pancreatitis by Diagnosis

      • Imaging Tests

      • Laboratory Tests




    • North America Acute Pancreatitis by End-user

      • Hospitals

      • Clinics

      • Others




    • US Outlook (USD Billion, 2018-2030)


    • US Acute Pancreatitis by Cause

      • Gallstones

      • Alcohol

      • Others




    • US Acute Pancreatitis by Treatment

      • Intravenous fluid

      • Nutritional support

      • Analgesics

      • Endoscopic Retrograde Cholangiopancreatography (ERCP)

      • Others




    • US Acute Pancreatitis by Diagnosis

      • Imaging Tests

      • Laboratory Tests




    • US Acute Pancreatitis by End-user

      • Hospitals

      • Clinics

      • Others




    • CANADA Outlook (USD Billion, 2018-2030)


    • CANADA Acute Pancreatitis by Cause

      • Gallstones

      • Alcohol

      • Others




    • CANADA Acute Pancreatitis by Treatment

      • Intravenous fluid

      • Nutritional support

      • Analgesics

      • Endoscopic Retrograde Cholangiopancreatography (ERCP)

      • Others




    • CANADA Acute Pancreatitis by Diagnosis

      • Imaging Tests

      • Laboratory Tests




    • CANADA Acute Pancreatitis by End-user

      • Hospitals

      • Clinics

      • Others




    • Europe Outlook (USD Billion, 2018-2030)


      • Europe Acute Pancreatitis by Cause

        • Gallstones

        • Alcohol

        • Others




      • Europe Acute Pancreatitis by Treatment

        • Intravenous fluid

        • Nutritional support

        • Analgesics

        • Endoscopic Retrograde Cholangiopancreatography (ERCP)

        • Others




      • Europe Acute Pancreatitis by Diagnosis

        • Imaging Tests

        • Laboratory Tests




      • Europe Acute Pancreatitis by End-user

        • Hospitals

        • Clinics

        • Others



      • Germany Outlook (USD Billion, 2018-2030)


      • Germany Acute Pancreatitis by Cause

        • Gallstones

        • Alcohol

        • Others




      • Germany Acute Pancreatitis by Treatment

        • Intravenous fluid

        • Nutritional support

        • Analgesics

        • Endoscopic Retrograde Cholangiopancreatography (ERCP)

        • Others




      • Germany Acute Pancreatitis by Diagnosis

        • Imaging Tests

        • Laboratory Tests




      • Germany Acute Pancreatitis by End-user

        • Hospitals

        • Clinics

        • Others



      • France Outlook (USD Billion, 2018-2030)


      • France Acute Pancreatitis by Cause

        • Gallstones

        • Alcohol

        • Others




      • France Acute Pancreatitis by Treatment

        • Intravenous fluid

        • Nutritional support

        • Analgesics

        • Endoscopic Retrograde Cholangiopancreatography (ERCP)

        • Others




      • France Acute Pancreatitis by Diagnosis

        • Imaging Tests

        • Laboratory Tests




      • France Acute Pancreatitis by End-user

        • Hospitals

        • Clinics

        • Others




      • UK Outlook (USD Billion, 2018-2030)


      • UK Acute Pancreatitis by Cause

        • Gallstones

        • Alcohol

        • Others




      • UK Acute Pancreatitis by Treatment

        • Intravenous fluid

        • Nutritional support

        • Analgesics

        • Endoscopic Retrograde Cholangiopancreatography (ERCP)

        • Others




      • UK Acute Pancreatitis by Diagnosis

        • Imaging Tests

        • Laboratory Tests




      • UK Acute Pancreatitis by End-user

        • Hospitals

        • Clinics

        • Others




      • ITALY Outlook (USD Billion, 2018-2030)


      • ITALY Acute Pancreatitis by Cause

        • Gallstones

        • Alcohol

        • Others




      • ITALY Acute Pancreatitis by Treatment

        • Intravenous fluid

        • Nutritional support

        • Analgesics

        • Endoscopic Retrograde Cholangiopancreatography (ERCP)

        • Others




      • ITALY Acute Pancreatitis by Diagnosis

        • Imaging Tests

        • Laboratory Tests




      • ITALY Acute Pancreatitis by End-user

        • Hospitals

        • Clinics

        • Others




      • SPAIN Outlook (USD Billion, 2018-2030)


      • Spain Acute Pancreatitis by Cause

        • Gallstones

        • Alcohol

        • Others




      • Spain Acute Pancreatitis by Treatment

        • Intravenous fluid

        • Nutritional support

        • Analgesics

        • Endoscopic Retrograde Cholangiopancreatography (ERCP)

        • Others




      • Spain Acute Pancreatitis by Diagnosis

        • Imaging Tests

        • Laboratory Tests




      • Spain Acute Pancreatitis by End-user

        • Hospitals

        • Clinics

        • Others




      • Rest Of Europe Outlook (USD Billion, 2018-2030)


      • Rest Of Europe Acute Pancreatitis by Cause

        • Gallstones

        • Alcohol

        • Others




      • REST OF EUROPE Acute Pancreatitis by Treatment

        • Intravenous fluid

        • Nutritional support

        • Analgesics

        • Endoscopic Retrograde Cholangiopancreatography (ERCP)

        • Others




      • REST OF EUROPE Acute Pancreatitis by Diagnosis

        • Imaging Tests

        • Laboratory Tests




      • REST OF EUROPE Acute Pancreatitis by End-user

        • Hospitals

        • Clinics

        • Others




      • Asia-Pacific Outlook (USD Billion, 2018-2030)


        • Asia-Pacific Acute Pancreatitis by Cause

          • Gallstones

          • Alcohol

          • Others




        • Asia-Pacific Acute Pancreatitis by Treatment

          • Intravenous fluid

          • Nutritional support

          • Analgesics

          • Endoscopic Retrograde Cholangiopancreatography (ERCP)

          • Others




        • Asia-Pacific Acute Pancreatitis by Diagnosis

          • Imaging Tests

          • Laboratory Tests




        • Asia-Pacific Acute Pancreatitis by End-user

          • Hospitals

          • Clinics

          • Others




        • China Outlook (USD Billion, 2018-2030)


        • China Acute Pancreatitis by Cause

          • Gallstones

          • Alcohol

          • Others




        • China Acute Pancreatitis by Treatment

          • Intravenous fluid

          • Nutritional support

          • Analgesics

          • Endoscopic Retrograde Cholangiopancreatography (ERCP)

          • Others




        • China Acute Pancreatitis by Diagnosis

          • Imaging Tests

          • Laboratory Tests




        • China Acute Pancreatitis by End-user

          • Hospitals

          • Clinics

          • Others




        • Japan Outlook (USD Billion, 2018-2030)


        • Japan Acute Pancreatitis by Cause

          • Gallstones

          • Alcohol

          • Others




        • Japan Acute Pancreatitis by Treatment

          • Intravenous fluid

          • Nutritional support

          • Analgesics

          • Endoscopic Retrograde Cholangiopancreatography (ERCP)

          • Others




        • Japan Acute Pancreatitis by Diagnosis

          • Imaging Tests

          • Laboratory Tests




        • Japan Acute Pancreatitis by End-user

          • Hospitals

          • Clinics

          • Others




        • India Outlook (USD Billion, 2018-2030)


        • India Acute Pancreatitis by Cause

          • Gallstones

          • Alcohol

          • Others




        • India Acute Pancreatitis by Treatment

          • Intravenous fluid

          • Nutritional support

          • Analgesics

          • Endoscopic Retrograde Cholangiopancreatography (ERCP)

          • Others




        • India Acute Pancreatitis by Diagnosis

          • Imaging Tests

          • Laboratory Tests




        • India Acute Pancreatitis by End-user

          • Hospitals

          • Clinics

          • Others




        • Australia Outlook (USD Billion, 2018-2030)


        • Australia Acute Pancreatitis by Cause

          • Gallstones

          • Alcohol

          • Others




        • Australia Acute Pancreatitis by Treatment

          • Intravenous fluid

          • Nutritional support

          • Analgesics

          • Endoscopic Retrograde Cholangiopancreatography (ERCP)

          • Others




        • Australia Acute Pancreatitis by Diagnosis

          • Imaging Tests

          • Laboratory Tests




        • Australia Acute Pancreatitis by End-user

          • Hospitals

          • Clinics

          • Others




        • Rest of Asia-Pacific Outlook (USD Billion, 2018-2030)


        • Rest of Asia-Pacific Acute Pancreatitis by Cause

          • Gallstones

          • Alcohol

          • Others




        • Rest of Asia-Pacific Acute Pancreatitis by Treatment

          • Intravenous fluid

          • Nutritional support

          • Analgesics

          • Endoscopic Retrograde Cholangiopancreatography (ERCP)

          • Others




        • Rest of Asia-Pacific Acute Pancreatitis by Diagnosis

          • Imaging Tests

          • Laboratory Tests




        • Rest of Asia-Pacific Acute Pancreatitis by End-user

          • Hospitals

          • Clinics

          • Others




        • Rest of the World Outlook (USD Billion, 2018-2030)


          • Rest of the World Acute Pancreatitis by Cause

            • Gallstones

            • Alcohol

            • Others




          • Rest of the World Acute Pancreatitis by Treatment

            • Intravenous fluid

            • Nutritional support

            • Analgesics

            • Endoscopic Retrograde Cholangiopancreatography (ERCP)

            • Others




          • Rest of the World Acute Pancreatitis by Diagnosis

            • Imaging Tests

            • Laboratory Tests




          • Rest of the World Acute Pancreatitis by End-user

            • Hospitals

            • Clinics

            • Others




          • Middle East Outlook (USD Billion, 2018-2030)


          • Middle East Acute Pancreatitis by Cause

            • Gallstones

            • Alcohol

            • Others




          • Middle East Acute Pancreatitis by Treatment

            • Intravenous fluid

            • Nutritional support

            • Analgesics

            • Endoscopic Retrograde Cholangiopancreatography (ERCP)

            • Others




          • Middle East Acute Pancreatitis by Diagnosis

            • Imaging Tests

            • Laboratory Tests




          • Middle East Acute Pancreatitis by End-user

            • Hospitals

            • Clinics

            • Others




          • Africa Outlook (USD Billion, 2018-2030)


          • Africa Acute Pancreatitis by Cause

            • Gallstones

            • Alcohol

            • Others




          • Africa Acute Pancreatitis by Treatment

            • Intravenous fluid

            • Nutritional support

            • Analgesics

            • Endoscopic Retrograde Cholangiopancreatography (ERCP)

            • Others




          • Africa Acute Pancreatitis by Diagnosis

            • Imaging Tests

            • Laboratory Tests




          • Africa Acute Pancreatitis by End-user

            • Hospitals

            • Clinics

            • Others




          • Latin America Outlook (USD Billion, 2018-2030)


          • Latin America Acute Pancreatitis by Cause

            • Gallstones

            • Alcohol

            • Others




          • Latin America Acute Pancreatitis by Treatment

            • Intravenous fluid

            • Nutritional support

            • Analgesics

            • Endoscopic Retrograde Cholangiopancreatography (ERCP)

            • Others




          • Latin America Acute Pancreatitis by Diagnosis

            • Imaging Tests

            • Laboratory Tests




          • Latin America Acute Pancreatitis by End-user

            • Hospitals

            • Clinics

            • Others











Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Please fill in Business Email for Quick Response

1 EXECUTIVE SUMMARY

1.1 OVERVIEW 14

1.1.1 MARKET SYNOPSIS 14

2 MARKET INTRODUCTION

2.1 SCOPE OF THE STUDY 15

2.2 RESEARCH OBJECTIVE 15

2.3 LIST OF ASSUMPTIONS 15

3 RESEARCH METHODOLOGY

3.1 OVERVIEW 17

3.2 DATA MINING 17

3.3 SECONDARY RESEARCH 18

3.4 PRIMARY RESEARCH 18

3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 19

3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS 19

3.5 FORECASTING TECHNIQUES 20

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 21

3.6.1 BOTTOM-UP APPROACH 21

3.6.2 TOP-DOWN APPROACH 22

3.7 DATA TRIANGULATION 22

3.8 VALIDATION 23

4 MARKET DYNAMICS

4.1 OVERVIEW 24

4.2 DRIVERS 25

4.2.1 RISING PREVALENCE OF GALLSTONES 25

4.2.2 HIGH CONSUMPTION OF ALCOHOL 25

4.3 RESTRAINTS 26

4.3.1 STRINGENT REGULATORY STANDARDS OF THE FOOD DRUG AND ADMINISTRATION 26

4.4 OPPORTUNITIES 26

4.4.1 STRONG PIPELINE 26

5 MARKET FACTOR ANALYSIS

5.1 PORTERโ€™S FIVE FORCES MODEL 27

5.1.1 THREAT OF NEW ENTRANTS 27

5.1.2 BARGAINING POWER OF SUPPLIERS 28

5.1.3 THREAT OF SUBSTITUTES 28

5.1.4 BARGAINING POWER OF BUYERS 28

5.1.5 INTENSITY OF RIVALRY 28

5.2 VALUE CHAIN ANALYSIS 29

5.2.1 R&D AND DESIGNING 30

5.2.2 MANUFACTURING 30

5.2.3 DISTRIBUTION 30

5.2.4 MARKETING & SALES 30

5.2.5 POST-SALES MONITORING 30

5.3 EPIDEMIOLOGY DATA 31

5.4 REGULATORY SCENARIO 31

5.5 PIPELINE ANALYSIS 31

6 ACUTE PANCREATITIS, BY CAUSE

6.1 OVERVIEW 34

6.2 GALLSTONES 35

6.3 ALCOHOL 36

6.4 OTHER CAUSES 36

7 ACUTE PANCREATITIS, BY TREATMENT & DIAGNOSIS

7.1 OVERVIEW 37

7.2 TREATMENT 39

7.3 DIAGNOSIS 39

8 ACUTE PANCREATITIS, BY END USER

8.1 OVERVIEW 41

8.2 HOSPIATLS & CLINICS 42

8.3 OTHERS 42

9 GLOBAL ACUTE PANCREATITIS, BY REGION

9.1 OVERVIEW 43

9.2 AMERICAS 45

ACUTE PANCREATITIS, BY CAUSE

ACUTE PANCREATITIS, BY TREATMENT & DIAGNOSIS

ACUTE PANCREATITIS, BY END USER

9.2.1 NORTH AMERICA 47

ACUTE PANCREATITIS, BY CAUSE

ACUTE PANCREATITIS, BY TREATMENT & DIAGNOSIS

ACUTE PANCREATITIS, BY END USER

9.2.1.1 US 49

ACUTE PANCREATITIS, BY CAUSE

ACUTE PANCREATITIS, BY TREATMENT & DIAGNOSIS

ACUTE PANCREATITIS, BY END USER

9.2.1.2 CANADA 51

ACUTE PANCREATITIS, BY CAUSE

ACUTE PANCREATITIS, BY TREATMENT & DIAGNOSIS

ACUTE PANCREATITIS, BY END USER

9.2.2 LATIN AMERICA 52

ACUTE PANCREATITIS, BY CAUSE

ACUTE PANCREATITIS, BY TREATMENT & DIAGNOSIS

ACUTE PANCREATITIS, BY END USER

9.3 EUROPE 54

ACUTE PANCREATITIS, BY CAUSE

ACUTE PANCREATITIS, BY TREATMENT & DIAGNOSIS

ACUTE PANCREATITIS, BY END USER

9.3.1 WESTERN EUROPE 56

ACUTE PANCREATITIS, BY CAUSE

ACUTE PANCREATITIS, BY TREATMENT & DIAGNOSIS

ACUTE PANCREATITIS, BY END USER

9.3.1.1 GERMANY 58

ACUTE PANCREATITIS, BY CAUSE

ACUTE PANCREATITIS, BY TREATMENT & DIAGNOSIS

ACUTE PANCREATITIS, BY END USER

9.3.1.2 FRANCE 60

ACUTE PANCREATITIS, BY CAUSE

ACUTE PANCREATITIS, BY TREATMENT & DIAGNOSIS

ACUTE PANCREATITIS, BY END USER

9.3.1.3 UK 61

ACUTE PANCREATITIS, BY CAUSE

ACUTE PANCREATITIS, BY TREATMENT & DIAGNOSIS

ACUTE PANCREATITIS, BY END USER

9.3.1.4 ITALY 63

ACUTE PANCREATITIS, BY CAUSE

ACUTE PANCREATITIS, BY TREATMENT & DIAGNOSIS

ACUTE PANCREATITIS, BY END USER

9.3.1.5 SPAIN 64

ACUTE PANCREATITIS, BY CAUSE

ACUTE PANCREATITIS, BY TREATMENT & DIAGNOSIS

ACUTE PANCREATITIS, BY END USER

9.3.1.6 REST OF WESTERN EUROPE 66

ACUTE PANCREATITIS, BY CAUSE

ACUTE PANCREATITIS, BY TREATMENT & DIAGNOSIS

ACUTE PANCREATITIS, BY END USER

9.3.2 EASTERN EUROPE 67

ACUTE PANCREATITIS, BY CAUSE

ACUTE PANCREATITIS, BY TREATMENT & DIAGNOSIS

ACUTE PANCREATITIS, BY END USER

9.4 ASIA-PACIFIC 70

ACUTE PANCREATITIS, BY CAUSE

ACUTE PANCREATITIS, BY TREATMENT & DIAGNOSIS

ACUTE PANCREATITIS, BY END USER

9.4.1 JAPAN 72

ACUTE PANCREATITIS, BY CAUSE

ACUTE PANCREATITIS, BY TREATMENT & DIAGNOSIS

ACUTE PANCREATITIS, BY END USER

9.4.2 CHINA 74

ACUTE PANCREATITIS, BY CAUSE

ACUTE PANCREATITIS, BY TREATMENT & DIAGNOSIS

ACUTE PANCREATITIS, BY END USER

9.4.3 INDIA 75

ACUTE PANCREATITIS, BY CAUSE

ACUTE PANCREATITIS, BY TREATMENT & DIAGNOSIS

ACUTE PANCREATITIS, BY END USER

9.4.4 AUSTRALIA 77

ACUTE PANCREATITIS, BY CAUSE

ACUTE PANCREATITIS, BY TREATMENT & DIAGNOSIS

ACUTE PANCREATITIS, BY END USER

9.4.5 SOUTH KOREA 78

ACUTE PANCREATITIS, BY CAUSE

ACUTE PANCREATITIS, BY TREATMENT & DIAGNOSIS

ACUTE PANCREATITIS, BY END USER

9.4.6 REST OF ASIA-PACIFIC 80

ACUTE PANCREATITIS, BY CAUSE

ACUTE PANCREATITIS, BY TREATMENT & DIAGNOSIS

ACUTE PANCREATITIS, BY END USER

9.5 MIDDLE EAST & AFRICA 82

ACUTE PANCREATITIS, BY CAUSE

ACUTE PANCREATITIS, BY TREATMENT & DIAGNOSIS

ACUTE PANCREATITIS, BY END USER

9.5.1 MIDDLE EAST 84

ACUTE PANCREATITIS, BY CAUSE

ACUTE PANCREATITIS, BY TREATMENT & DIAGNOSIS

ACUTE PANCREATITIS, BY END USER

9.5.2 AFRICA 86

ACUTE PANCREATITIS, BY CAUSE

ACUTE PANCREATITIS, BY TREATMENT & DIAGNOSIS

ACUTE PANCREATITIS, BY END USER

10 COMPETITIVE LANDSCAPE

10.1 OVERVIEW 88

11 COMPANY PROFILES

11.1 CALCIMEDICA 89

11.1.1 COMPANY OVERVIEW 89

11.1.2 FINANCIAL OVERVIEW 89

11.1.3 PRODUCTS/SERVICES OFFERED 89

11.1.4 KEY DEVELOPMENTS 89

11.1.5 SWOT ANALYSIS 90

11.1.6 KEY STRATEGIES 90

11.2 SCM LIFESCIENCE 91

11.2.1 COMPANY OVERVIEW 91

11.2.2 FINANCIAL OVERVIEW 91

11.2.3 PRODUCTS/SERVICES OFFERED 91

11.2.4 KEY DEVELOPMENTS 91

11.2.5 SWOT ANALYSIS 92

11.2.6 KEY STRATEGIES 92

11.3 SAMSUNG BIOEPIS 93

11.3.1 COMPANY OVERVIEW 93

11.3.2 FINANCIAL OVERVIEW 93

11.3.3 PRODUCTS/SERVICES OFFERED 93

11.3.4 KEY DEVELOPMENTS 93

11.3.5 SWOT ANALYSIS 94

11.3.6 KEY STRATEGIES 94

11.4 GNT PHARMA CO., LTD 95

11.4.1 COMPANY OVERVIEW 95

11.4.2 FINANCIAL OVERVIEW 95

11.4.3 PRODUCTS/SERVICES OFFERED 95

11.4.4 KEY DEVELOPMENTS 95

11.4.5 SWOT ANALYSIS 96

11.4.6 KEY STRATEGIES 96

11.5 BAXTER INTERNATIONAL INC. 97

11.5.1 COMPANY OVERVIEW 97

11.5.2 FINANCIAL OVERVIEW 97

11.5.3 PRODUCTS/SERVICES OFFERED 98

11.5.4 KEY DEVELOPMENTS 98

11.5.5 SWOT ANALYSIS 99

11.5.6 KEY STRATEGIES 99

11.6 B. BRAUN MELSUNGEN AG 100

11.6.1 COMPANY OVERVIEW 100

11.6.2 FINANCIAL OVERVIEW 101

11.6.3 PRODUCTS/SERVICES OFFERED 101

11.6.4 KEY DEVELOPMENTS 102

11.6.5 SWOT ANALYSIS 102

11.6.6 KEY STRATEGIES 102

11.7 GENERAL ELECTRIC COMPANY 103

11.7.1 COMPANY OVERVIEW 103

11.7.2 FINANCIAL OVERVIEW 103

11.7.3 PRODUCTS/SERVICES OFFERED 104

11.7.4 KEY DEVELOPMENTS 104

11.7.5 SWOT ANALYSIS 105

11.7.6 KEY STRATEGIES 105

11.8 MEDTRONIC 106

11.8.1 COMPANY OVERVIEW 106

11.8.2 FINANCIAL OVERVIEW 106

11.8.3 PRODUCTS/SERVICES OFFERED 107

11.8.4 KEY DEVELOPMENTS 107

11.8.5 SWOT ANALYSIS 107

11.8.6 KEY STRATEGIES 108

11.9 BOSTON SCIENTIFIC CORPORATION 109

11.9.1 COMPANY OVERVIEW 109

11.9.2 FINANCIAL OVERVIEW 109

11.9.3 PRODUCTS/SERVICES OFFERED 110

11.9.4 KEY DEVELOPMENTS 110

11.9.5 SWOT ANALYSIS 110

11.9.6 KEY STRATEGIES 111

11.10 FRESENIUS KABI USA 112

11.10.1 COMPANY OVERVIEW 112

11.10.2 FINANCIAL OVERVIEW 112

11.10.3 PRODUCTS/SERVICES OFFERED 113

11.10.4 KEY DEVELOPMENTS 113

11.10.5 SWOT ANALYSIS 114

11.10.6 KEY STRATEGIES 114

12 APPENDIX

12.1 REFERENCES 115

12.2 RELATED REPORTS 115

13 LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS 15

TABLE 2 PRODUCT PIPELINE 32

TABLE 3 GLOBAL ACUTE PANCREATITIS MARKET, BY CAUSE, 2020โ€“2027 (USD MILLION) 35

TABLE 4 GLOBAL ACUTE PANCREATITIS MARKET FOR GALLSTONES, BY REGION, 2020โ€“2027 (USD MILLION) 35

TABLE 5 GLOBAL ACUTE PANCREATITIS MARKET FOR ALCOHOL, BY REGION, 2020โ€“2027 (USD MILLION) 36

TABLE 6 GLOBAL ACUTE PANCREATITIS MARKET, BY TREATMENT & DIAGNOSIS, 2020โ€“2027 (USD MILLION) 38

TABLE 7 GLOBAL ACUTE PANCREATITIS MARKET FOR TREATMENT, BY TYPE, 2020โ€“2027 (USD MILLION) 39

TABLE 8 GLOBAL ACUTE PANCREATITIS MARKET FOR TREATMENT, BY REGION, 2020โ€“2027 (USD MILLION) 39

TABLE 9 GLOBAL ACUTE PANCREATITIS MARKET FOR DIAGNOSIS, BY TYPE, 2020โ€“2027 (USD MILLION) 39

TABLE 10 GLOBAL ACUTE PANCREATITIS MARKET FOR DIAGNOSIS, BY REGION, 2020โ€“2027 (USD MILLION) 40

TABLE 11 GLOBAL ACUTE PANCREATITIS MARKET, BY END USER, 2020โ€“2027 (USD MILLION) 41

TABLE 12 GLOBAL ACUTE PANCREATITIS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020โ€“2027 (USD MILLION) 42

TABLE 13 GLOBAL ACUTE PANCREATITIS MARKET, BY REGION, 2020โ€“2027 (USD MILLION) 44

TABLE 14 AMERICAS: ACUTE PANCREATITIS MARKET, BY REGION, 2020โ€“2027 (USD MILLION) 45

TABLE 15 AMERICAS: ACUTE PANCREATITIS MARKET, BY CAUSE, 2020โ€“2027 (USD MILLION) 45

TABLE 16 AMERICAS: ACUTE PANCREATITIS MARKET, BY TREATMENT & DIAGNOSIS, 2020โ€“2027 (USD MILLION) 46

TABLE 17 AMERICAS: ACUTE PANCREATITIS MARKET, FOR TREATMENT, BY TYPE, 2020โ€“2027 (USD MILLION) 46

TABLE 18 AMERICAS: ACUTE PANCREATITIS MARKET, FOR DIAGNOSIS, BY TYPE, 2020โ€“2027 (USD MILLION) 46

TABLE 19 AMERICAS: ACUTE PANCREATITIS MARKET, BY END USER, 2020โ€“2027 (USD MILLION) 47

TABLE 20 NORTH AMERICA: ACUTE PANCREATITIS MARKET, BY COUNTRY, 2020โ€“2027 (USD MILLION) 47

TABLE 21 NORTH AMERICA: ACUTE PANCREATITIS MARKET, BY CAUSE, 2020โ€“2027 (USD MILLION) 47

TABLE 22 NORTH AMERICA: ACUTE PANCREATITIS MARKET, BY TREATMENT & DIAGNOSIS, 2020โ€“2027 (USD MILLION) 48

TABLE 23 NORTH AMERICA: ACUTE PANCREATITIS MARKET, FOR TREATMENT, BY TYPE, 2020โ€“2027 (USD MILLION) 48

TABLE 24 NORTH AMERICA: ACUTE PANCREATITIS MARKET, FOR DIAGNOSIS, BY TYPE, 2020โ€“2027 (USD MILLION) 48

TABLE 25 NORTH AMERICA: ACUTE PANCREATITIS MARKET, BY END USER, 2020โ€“2027 (USD MILLION) 49

TABLE 26 US: ACUTE PANCREATITIS MARKET, BY CAUSE, 2020โ€“2027 (USD MILLION) 49

TABLE 27 US: ACUTE PANCREATITIS MARKET, BY TREATMENT & DIAGNOSIS, 2020โ€“2027 (USD MILLION) 49

TABLE 28 US: ACUTE PANCREATITIS MARKET, FOR TREATMENT, BY TYPE, 2020โ€“2027 (USD MILLION) 50

TABLE 29 US: ACUTE PANCREATITIS MARKET, FOR DIAGNOSIS, BY TYPE, 2020โ€“2027 (USD MILLION) 50

TABLE 30 US: ACUTE PANCREATITIS MARKET, BY END USER, 2020โ€“2027 (USD MILLION) 50

TABLE 31 CANADA: ACUTE PANCREATITIS MARKET, BY CAUSE, 2020โ€“2027 (USD MILLION) 51

TABLE 32 CANADA: ACUTE PANCREATITIS MARKET, BY TREATMENT & DIAGNOSIS, 2020โ€“2027 (USD MILLION) 51

TABLE 33 CANADA: ACUTE PANCREATITIS MARKET, FOR TREATMENT, BY TYPE, 2020โ€“2027 (USD MILLION) 51

TABLE 34 CANADA: ACUTE PANCREATITIS MARKET, FOR DIAGNOSIS, BY TYPE, 2020โ€“2027 (USD MILLION) 52

TABLE 35 CANADA: ACUTE PANCREATITIS MARKET, BY END USER, 2020โ€“2027 (USD MILLION) 52

TABLE 36 LATIN AMERICA: ACUTE PANCREATITIS MARKET, BY CAUSE, 2020โ€“2027 (USD MILLION) 52

TABLE 37 LATIN AMERICA: ACUTE PANCREATITIS MARKET, BY TREATMENT & DIAGNOSIS, 2020โ€“2027 (USD MILLION) 52

TABLE 38 LATIN AMERICA: ACUTE PANCREATITIS MARKET, FOR TREATMENT, BY TYPE, 2020โ€“2027 (USD MILLION) 53

TABLE 39 LATIN AMERICA: ACUTE PANCREATITIS MARKET, FOR DIAGNOSIS, BY TYPE, 2020โ€“2027 (USD MILLION) 53

TABLE 40 LATIN AMERICA: ACUTE PANCREATITIS MARKET, BY END USER, 2020โ€“2027 (USD MILLION) 53

TABLE 41 EUROPE: ACUTE PANCREATITIS MARKET, BY REGION, 2020โ€“2027 (USD MILLION) 54

TABLE 42 EUROPE: ACUTE PANCREATITIS MARKET, BY CAUSE, 2020โ€“2027 (USD MILLION) 54

TABLE 43 EUROPE: ACUTE PANCREATITIS MARKET, BY TREATMENT & DIAGNOSIS, 2020โ€“2027 (USD MILLION) 55

TABLE 44 EUROPE: ACUTE PANCREATITIS MARKET, FOR TREATMENT, BY TYPE, 2020โ€“2027 (USD MILLION) 55

TABLE 45 EUROPE: ACUTE PANCREATITIS MARKET, FOR DIAGNOSIS, BY TYPE, 2020โ€“2027 (USD MILLION) 55

TABLE 46 EUROPE: ACUTE PANCREATITIS MARKET, BY END USER, 2020โ€“2027 (USD MILLION) 56

TABLE 47 WESTERN EUROPE: ACUTE PANCREATITIS MARKET, BY COUNTRY, 2020โ€“2027 (USD MILLION) 56

TABLE 48 WESTERN EUROPE: ACUTE PANCREATITIS MARKET, BY CAUSE, 2020โ€“2027 (USD MILLION) 56

TABLE 49 WESTERN EUROPE: ACUTE PANCREATITIS MARKET, BY TREATMENT & DIAGNOSIS, 2020โ€“2027 (USD MILLION) 57

TABLE 50 WESTERN EUROPE: ACUTE PANCREATITIS MARKET, FOR TREATMENT, BY TYPE, 2020โ€“2027 (USD MILLION) 57

TABLE 51 WESTERN EUROPE: ACUTE PANCREATITIS MARKET, FOR DIAGNOSIS, BY TYPE, 2020โ€“2027 (USD MILLION) 57

TABLE 52 WESTERN EUROPE: ACUTE PANCREATITIS MARKET, BY END USER, 2020โ€“2027 (USD MILLION) 58

TABLE 53 GERMANY: ACUTE PANCREATITIS MARKET, BY CAUSE, 2020โ€“2027 (USD MILLION) 58

TABLE 54 GERMANY: ACUTE PANCREATITIS MARKET, BY TREATMENT & DIAGNOSIS, 2020โ€“2027 (USD MILLION) 58

TABLE 55 GERMANY: ACUTE PANCREATITIS MARKET, FOR TREATMENT, BY TYPE, 2020โ€“2027 (USD MILLION) 59

TABLE 56 GERMANY: ACUTE PANCREATITIS MARKET, FOR DIAGNOSIS, BY TYPE, 2020โ€“2027 (USD MILLION) 59

TABLE 57 GERMANY: ACUTE PANCREATITIS MARKET, BY END USER, 2020โ€“2027 (USD MILLION) 59

TABLE 58 FRANCE: ACUTE PANCREATITIS MARKET, BY CAUSE, 2020โ€“2027 (USD MILLION) 60

TABLE 59 FRANCE: ACUTE PANCREATITIS MARKET, BY TREATMENT & DIAGNOSIS, 2020โ€“2027 (USD MILLION) 60

TABLE 60 FRANCE: ACUTE PANCREATITIS MARKET, FOR TREATMENT, BY TYPE, 2020โ€“2027 (USD MILLION) 60

TABLE 61 FRANCE: ACUTE PANCREATITIS MARKET, FOR DIAGNOSIS, BY TYPE, 2020โ€“2027 (USD MILLION) 61

TABLE 62 FRANCE: ACUTE PANCREATITIS MARKET, BY END USER, 2020โ€“2027 (USD MILLION) 61

TABLE 63 UK: ACUTE PANCREATITIS MARKET, BY CAUSE, 2020โ€“2027 (USD MILLION) 61

TABLE 64 UK: ACUTE PANCREATITIS MARKET, BY TREATMENT & DIAGNOSIS, 2020โ€“2027 (USD MILLION) 61

TABLE 65 UK: ACUTE PANCREATITIS MARKET, FOR TREATMENT, BY TYPE, 2020โ€“2027 (USD MILLION) 62

TABLE 66 UK: ACUTE PANCREATITIS MARKET, FOR DIAGNOSIS, BY TYPE, 2020โ€“2027 (USD MILLION) 62

TABLE 67 UK: ACUTE PANCREATITIS MARKET, BY END USER, 2020โ€“2027 (USD MILLION) 62

TABLE 68 ITALY: ACUTE PANCREATITIS MARKET, BY CAUSE, 2020โ€“2027 (USD MILLION) 63

TABLE 69 ITALY: ACUTE PANCREATITIS MARKET, BY TREATMENT & DIAGNOSIS, 2020โ€“2027 (USD MILLION) 63

TABLE 70 ITALY: ACUTE PANCREATITIS MARKET, FOR TREATMENT, BY TYPE, 2020โ€“2027 (USD MILLION) 63

TABLE 71 ITALY: ACUTE PANCREATITIS MARKET, FOR DIAGNOSIS, BY TYPE, 2020โ€“2027 (USD MILLION) 64

TABLE 72 ITALY: ACUTE PANCREATITIS MARKET, BY END USER, 2020โ€“2027 (USD MILLION) 64

TABLE 73 SPAIN: ACUTE PANCREATITIS MARKET, BY CAUSE, 2020โ€“2027 (USD MILLION) 64

TABLE 74 SPAIN: ACUTE PANCREATITIS MARKET, BY TREATMENT & DIAGNOSIS, 2020โ€“2027 (USD MILLION) 64

TABLE 75 SPAIN: ACUTE PANCREATITIS MARKET, FOR TREATMENT, BY TYPE, 2020โ€“2027 (USD MILLION) 65

TABLE 76 SPAIN: ACUTE PANCREATITIS MARKET, FOR DIAGNOSIS, BY TYPE, 2020โ€“2027 (USD MILLION) 65

TABLE 77 SPAIN: ACUTE PANCREATITIS MARKET, BY END USER, 2020โ€“2027 (USD MILLION) 65

TABLE 78 REST OF WESTERN EUROPE: ACUTE PANCREATITIS MARKET, BY CAUSE, 2020โ€“2027 (USD MILLION) 66

TABLE 79 REST OF WESTERN EUROPE: ACUTE PANCREATITIS MARKET, BY TREATMENT & DIAGNOSIS, 2020โ€“2027 (USD MILLION) 66

TABLE 80 REST OF WESTERN EUROPE: ACUTE PANCREATITIS MARKET, FOR TREATMENT, BY TYPE, 2020โ€“2027 (USD MILLION) 66

TABLE 81 REST OF WESTERN EUROPE: ACUTE PANCREATITIS MARKET, FOR DIAGNOSIS, BY TYPE, 2020โ€“2027 (USD MILLION) 67

TABLE 82 REST OF WESTERN EUROPE: ACUTE PANCREATITIS MARKET, BY END USER, 2020โ€“2027 (USD MILLION) 67

TABLE 83 EASTERN EUROPE: ACUTE PANCREATITIS MARKET, BY CAUSE, 2020โ€“2027 (USD MILLION) 67

TABLE 84 EASTERN EUROPE: ACUTE PANCREATITIS MARKET, BY TREATMENT & DIAGNOSIS, 2020โ€“2027 (USD MILLION) 68

TABLE 85 EASTERN EUROPE: ACUTE PANCREATITIS MARKET, FOR TREATMENT, BY TYPE, 2020โ€“2027 (USD MILLION) 68

TABLE 86 EASTERN EUROPE: ACUTE PANCREATITIS MARKET, FOR DIAGNOSIS, BY TYPE, 2020โ€“2027 (USD MILLION) 68

TABLE 87 EASTERN EUROPE: ACUTE PANCREATITIS MARKET, BY END USER, 2020โ€“2027 (USD MILLION) 69

TABLE 88 ASIA-PACIFIC: ACUTE PANCREATITIS MARKET, BY COUNTRY, 2020โ€“2027 (USD MILLION) 70

TABLE 89 ASIA-PACIFIC: ACUTE PANCREATITIS MARKET, BY CAUSE, 2020โ€“2027 (USD MILLION) 70

TABLE 90 ASIA-PACIFIC: ACUTE PANCREATITIS MARKET, BY TREATMENT & DIAGNOSIS, 2020โ€“2027 (USD MILLION) 71

TABLE 91 ASIA-PACIFIC: ACUTE PANCREATITIS MARKET, FOR TREATMENT, BY TYPE, 2020โ€“2027 (USD MILLION) 71

TABLE 92 ASIA-PACIFIC: ACUTE PANCREATITIS MARKET, FOR DIAGNOSIS, BY TYPE, 2020โ€“2027 (USD MILLION) 71

TABLE 93 ASIA-PACIFIC: ACUTE PANCREATITIS MARKET, BY END USER, 2020โ€“2027 (USD MILLION) 72

TABLE 94 JAPAN: ACUTE PANCREATITIS MARKET, BY CAUSE, 2020โ€“2027 (USD MILLION) 72

TABLE 95 JAPAN: ACUTE PANCREATITIS MARKET, BY TREATMENT & DIAGNOSIS, 2020โ€“2027 (USD MILLION) 72

TABLE 96 JAPAN: ACUTE PANCREATITIS MARKET, FOR TREATMENT, BY TYPE, 2020โ€“2027 (USD MILLION) 73

TABLE 97 JAPAN: ACUTE PANCREATITIS MARKET, FOR DIAGNOSIS, BY TYPE, 2020โ€“2027 (USD MILLION) 73

TABLE 98 JAPAN: ACUTE PANCREATITIS MARKET, BY END USER, 2020โ€“2027 (USD MILLION) 73

TABLE 99 CHINA: ACUTE PANCREATITIS MARKET, BY CAUSE, 2020โ€“2027 (USD MILLION) 74

TABLE 100 CHINA: ACUTE PANCREATITIS MARKET, BY TREATMENT & DIAGNOSIS, 2020โ€“2027 (USD MILLION) 74

TABLE 101 CHINA: ACUTE PANCREATITIS MARKET, FOR TREATMENT, BY TYPE, 2020โ€“2027 (USD MILLION) 74

TABLE 102 CHINA: ACUTE PANCREATITIS MARKET, FOR DIAGNOSIS, BY TYPE, 2020โ€“2027 (USD MILLION) 75

TABLE 103 CHINA: ACUTE PANCREATITIS MARKET, BY END USER, 2020โ€“2027 (USD MILLION) 75

TABLE 104 INDIA: ACUTE PANCREATITIS MARKET, BY CAUSE, 2020โ€“2027 (USD MILLION) 75

TABLE 105 INDIA: ACUTE PANCREATITIS MARKET, BY TREATMENT & DIAGNOSIS, 2020โ€“2027 (USD MILLION) 75

TABLE 106 INDIA: ACUTE PANCREATITIS MARKET, FOR TREATMENT, BY TYPE, 2020โ€“2027 (USD MILLION) 76

TABLE 107 INDIA: ACUTE PANCREATITIS MARKET, FOR DIAGNOSIS, BY TYPE, 2020โ€“2027 (USD MILLION) 76

TABLE 108 INDIA: ACUTE PANCREATITIS MARKET, BY END USER, 2020โ€“2027 (USD MILLION) 76

TABLE 109 AUSTRALIA: ACUTE PANCREATITIS MARKET, BY CAUSE, 2020โ€“2027 (USD MILLION) 77

TABLE 110 AUSTRALIA: ACUTE PANCREATITIS MARKET, BY TREATMENT & DIAGNOSIS, 2020โ€“2027 (USD MILLION) 77

TABLE 111 AUSTRALIA: ACUTE PANCREATITIS MARKET, FOR TREATMENT, BY TYPE, 2020โ€“2027 (USD MILLION) 77

TABLE 112 AUSTRALIA: ACUTE PANCREATITIS MARKET, FOR DIAGNOSIS, BY TYPE, 2020โ€“2027 (USD MILLION) 78

TABLE 113 AUSTRALIA: ACUTE PANCREATITIS MARKET, BY END USER, 2020โ€“2027 (USD MILLION) 78

TABLE 114 SOUTH KOREA: ACUTE PANCREATITIS MARKET, BY CAUSE, 2020โ€“2027 (USD MILLION) 78

TABLE 115 SOUTH KOREA: ACUTE PANCREATITIS MARKET, BY TREATMENT & DIAGNOSIS, 2020โ€“2027 (USD MILLION) 78

TABLE 116 SOUTH KOREA: ACUTE PANCREATITIS MARKET, FOR TREATMENT, BY TYPE, 2020โ€“2027 (USD MILLION) 79

TABLE 117 SOUTH KOREA: ACUTE PANCREATITIS MARKET, FOR DIAGNOSIS, BY TYPE, 2020โ€“2027 (USD MILLION) 79

TABLE 118 SOUTH KOREA: ACUTE PANCREATITIS MARKET, BY END USER, 2020โ€“2027 (USD MILLION) 79

TABLE 119 REST OF ASIA-PACIFIC: ACUTE PANCREATITIS MARKET, BY CAUSE, 2020โ€“2027 (USD MILLION) 80

TABLE 120 REST OF ASIA-PACIFIC: ACUTE PANCREATITIS MARKET, BY TREATMENT & DIAGNOSIS, 2020โ€“2027 (USD MILLION) 80

TABLE 121 REST OF ASIA-PACIFIC: ACUTE PANCREATITIS MARKET, FOR TREATMENT, BY TYPE, 2020โ€“2027 (USD MILLION) 80

TABLE 122 REST OF ASIA-PACIFIC: ACUTE PANCREATITIS MARKET, FOR DIAGNOSIS, BY TYPE, 2020โ€“2027 (USD MILLION) 81

TABLE 123 REST OF ASIA-PACIFIC: ACUTE PANCREATITIS MARKET, BY END USER, 2020โ€“2027 (USD MILLION) 81

TABLE 124 MIDDLE EAST & AFRICA: ACUTE PANCREATITIS MARKET, BY REGION, 2020โ€“2027 (USD MILLION) 82

TABLE 125 MIDDLE EAST & AFRICA: ACUTE PANCREATITIS MARKET, BY CAUSE, 2020โ€“2027 (USD MILLION) 82

TABLE 126 MIDDLE EAST & AFRICA: ACUTE PANCREATITIS MARKET, BY TREATMENT & DIAGNOSIS, 2020โ€“2027 (USD MILLION) 83

TABLE 127 MIDDLE EAST & AFRICA: ACUTE PANCREATITIS MARKET, FOR TREATMENT, BY TYPE, 2020โ€“2027 (USD MILLION) 83

TABLE 128 MIDDLE EAST & AFRICA: ACUTE PANCREATITIS MARKET, FOR DIAGNOSIS, BY TYPE, 2020โ€“2027 (USD MILLION) 83

TABLE 129 MIDDLE EAST & AFRICA: ACUTE PANCREATITIS MARKET, BY END USER, 2020โ€“2027 (USD MILLION) 84

TABLE 130 MIDDLE EAST: ACUTE PANCREATITIS MARKET, BY CAUSE, 2020โ€“2027 (USD MILLION) 84

TABLE 131 MIDDLE EAST: ACUTE PANCREATITIS MARKET, BY TREATMENT & DIAGNOSIS, 2020โ€“2027 (USD MILLION) 84

TABLE 132 MIDDLE EAST: ACUTE PANCREATITIS MARKET, FOR TREATMENT, BY TYPE, 2020โ€“2027 (USD MILLION) 85

TABLE 133 MIDDLE EAST: ACUTE PANCREATITIS MARKET, FOR DIAGNOSIS, BY TYPE, 2020โ€“2027 (USD MILLION) 85

TABLE 134 MIDDLE EAST: ACUTE PANCREATITIS MARKET, BY END USER, 2020โ€“2027 (USD MILLION) 85

TABLE 135 AFRICA: ACUTE PANCREATITIS MARKET, BY CAUSE, 2020โ€“2027 (USD MILLION) 86

TABLE 136 AFRICA: ACUTE PANCREATITIS MARKET, BY TREATMENT & DIAGNOSIS, 2020โ€“2027 (USD MILLION) 86

TABLE 137 AFRICA: ACUTE PANCREATITIS MARKET, FOR TREATMENT, BY TYPE, 2020โ€“2027 (USD MILLION) 86

TABLE 138 AFRICA: ACUTE PANCREATITIS MARKET, FOR DIAGNOSIS, BY TYPE, 2020โ€“2027 (USD MILLION) 87

TABLE 139 AFRICA: ACUTE PANCREATITIS MARKET, BY END USER, 2020โ€“2027 (USD MILLION) 87

TABLE 140 CALCIMEDICA PRODUCTS/SERVICES OFFERED 89

TABLE 141 CALCIMEDICA: KEY DEVELOPMENTS 89

TABLE 142 SCM LIFESCIENCE PRODUCTS/SERVICES OFFERED 91

TABLE 143 SCM LIFESCIENCE: KEY DEVELOPMENTS 91

TABLE 144 TAKEDA PHARMACEUTICAL COMPANY LIMITED PRODUCTS/SERVICES OFFERED 93

TABLE 145 SAMSUNG BIOEPIS: KEY DEVELOPMENTS 93

TABLE 146 GNT PHARMA CO., LTD PRODUCTS/SERVICES OFFERED 95

TABLE 147 BAXTER INTERNATIONAL INC.: PRODUCTS/SERVICES OFFERED 98

TABLE 148 BAXTER INTERNATIONAL INC.: KEY DEVELOPMENTS 98

TABLE 149 B. BRAUN MELSUNGEN AG: PRODUCTS/SERVICES OFFERED 101

TABLE 150 GENERAL ELECTRIC COMPANY: PRODUCTS/SERVICES OFFERED 104

TABLE 151 MEDTRONIC PRODUCTS/SERVICES OFFERED 107

TABLE 152 BOSTON SCIENTIFIC CORPORATION: PRODUCTS/SERVICES OFFERED 110

TABLE 153 FRESENIUS KABI USA: PRODUCTS/SERVICES OFFERED 113

14 LIST OF FIGURES

FIGURE 1 GLOBAL ACUTE PANCREATITIS MARKET STRUCTURE 16

FIGURE 2 BOTTOM-UP AND TOP-DOWN APPROACHES 21

FIGURE 3 MARKET DYNAMICS: ANALYSIS OF GLOBAL ACUTE PANCREATITIS MARKET 24

FIGURE 4 DRIVER IMPACT ANALYSIS 25

FIGURE 5 RESTRAINT IMPACT ANALYSIS 26

FIGURE 6 PORTERโ€™S FIVE FORCES ANALYSIS: GLOBAL ACUTE PANCREATITIS MARKET 27

FIGURE 7 VALUE CHAIN ANALYSIS OF THE GLOBAL ACUTE PANCREATITIS MARKET 29

FIGURE 8 PIPELINE ANALYSIS 33

FIGURE 9 GLOBAL ACUTE PANCREATITIS MARKET, BY CAUSE, 2020 (% SHARE) 34

FIGURE 10 GLOBAL ACUTE PANCREATITIS MARKET, BY CAUSE 2020 & 2027 (USD MILLION) 35

FIGURE 11 GLOBAL ACUTE PANCREATITIS MARKET, BY TREATMENT & DIAGNOSIS, 2020 (% SHARE) 38

FIGURE 12 GLOBAL ACUTE PANCREATITIS MARKET, BY TREATMENT & DIAGNOSIS 2020 & 2027 (USD MILLION) 38

FIGURE 13 GLOBAL ACUTE PANCREATITIS MARKET, BY END USER, 2020 (% SHARE) 41

FIGURE 14 GLOBAL ACUTE PANCREATITIS MARKET, BY END USER 2020 & 2027 (USD MILLION) 42

FIGURE 15 GLOBAL ACUTE PANCREATITIS MARKET, BY REGION, 2020 (% SHARE) 44

FIGURE 16 GLOBAL ACUTE PANCREATITIS MARKET, BY REGION, 2020 & 2027 (USD MILLION) 44

FIGURE 17 AMERICAS ACUTE PANCREATITIS MARKET SHARE, BY REGION 2020 (%) 45

FIGURE 18 EUROPE ACUTE PANCREATITIS MARKET SHARE, BY REGION 2020 (%) 54

FIGURE 19 ASIA-PACIFIC ACUTE PANCREATITIS MARKET SHARE, BY COUNTRY 2020 (%) 70

FIGURE 20 MIDDLE EAST & AFRICA: ACUTE PANCREATITIS MARKET SHARE, BY COUNTRY 2020 (%) 82

FIGURE 21 CALCIMEDICA: SWOT ANALYSIS 90

FIGURE 22 SCM LIFESCIENCE: SWOT ANALYSIS 92

FIGURE 23 SAMSUNG BIOEPIS: SWOT ANALYSIS 94

FIGURE 24 GNT PHARMA CO., LTD: SWOT ANALYSIS 96

FIGURE 25 BAXTER INTERNATIONAL INC.: FINANCIAL OVERVIEW SNAPSHOT 97

FIGURE 26 BAXTER INTERNATIONAL INC.: SWOT ANALYSIS 99

FIGURE 27 B. BRAUN MELSUNGEN AG: FINANCIAL OVERVIEW SNAPSHOT 101

FIGURE 28 B. BRAUN MELSUNGEN AG: SWOT ANALYSIS 102

FIGURE 29 GENERAL ELECTRIC COMPANY: FINANCIAL OVERVIEW SNAPSHOT 103

FIGURE 30 GENERAL ELECTRIC COMPANY: SWOT ANALYSIS 105

FIGURE 31 MEDTRONIC: FINANCIAL OVERVIEW SNAPSHOT 106

FIGURE 32 MEDTRONIC: SWOT ANALYSIS 107

FIGURE 33 BOSTON SCIENTIFIC CORPORATION: FINANCIAL OVERVIEW SNAPSHOT 109

FIGURE 34 BOSTON SCIENTIFIC CORPORATION: SWOT ANALYSIS 110

FIGURE 35 FRESENIUS KABI USA: FINANCIAL OVERVIEW SNAPSHOT 112

FIGURE 36 FRESENIUS KABI USA: SWOT ANALYSIS 114

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.